The/DT/O amount/NN/O of/IN/O blood/NN/O surgical/JJ/O patients/NNS/O can/MD/O donate/VB/O and/CC/O store/VB/O before/IN/O surgery/NN/O can/MD/O be/VB/O increased/VBN/O by/IN/O the/DT/O new/JJ/O genetically/RB/O engineered/VBN/O drug/NN/O ,/,/O EPO/NNP/O ././O
EPO/NNP/O ,/,/O or/CC/O erythropoietin/NN/O ,/,/O is/VBZ/O a/DT/O protein/NN/O the/DT/O human/JJ/O body/NN/O makes/VBZ/O to/TO/O stimulate/VB/O the/DT/O growth/NN/O of/IN/O red/JJ/O blood/NN/O cells/NNS/O ././O
A/DT/O competing/VBG/O version/NN/O of/IN/O EPO/NNP/O is/VBZ/O being/VBG/O developed/VBN/O by/IN/O Genetics/NNP/B-ORG Institute/NNP/I-ORG Inc./NNP/I-ORG in/IN/O Cambridge/NNP/B-GPE ,/,/O Mass/NNP/B-GPE ././O
The/DT/O drug/NN/O is/VBZ/O being/VBG/O used/VBN/O primarily/RB/O to/TO/O treat/VB/O anemias/NNS/O ././O
A/DT/O new/JJ/O experiment/NN/O ,/,/O reported/VBN/O in/IN/O this/DT/O week/NN/O 's/POS/O New/NNP/B-ORG England/NNP/I-ORG Journal/NNP/I-ORG of/IN/I-ORG Medicine/NNP/I-ORG ,/,/O involved/VBD/O giving/VBG/O injections/NNS/O of/IN/O Amgen/NNP/B-ORG 's/POS/O EPO/NNP/O to/TO/O 23/CD/O patients/NNS/O who/WP/O wanted/VBD/O to/TO/O store/VB/O units/NNS/O of/IN/O their/PRP$/O own/JJ/O blood/NN/O ././O
The/DT/O patients/NNS/O began/VBD/O receiving/VBG/O EPO/NNP/O injections/NNS/O about/IN/O a/DT/O month/NN/O before/IN/O their/PRP$/O scheduled/VBN/O surgery/NN/O ././O
They/PRP/O then/RB/O began/VBD/O donating/VBG/O blood/NN/O twice/RB/O a/DT/O week/NN/O ,/,/O receiving/VBG/O an/DT/O EPO/NNP/O injection/NN/O each/DT/O time/NN/O ././O
If/IN/O tests/NNS/O indicated/VBD/O a/DT/O low/JJ/O number/NN/O of/IN/O red/JJ/O cells/NNS/O ,/,/O blood/NN/O was/VBD/O n't/RB/O taken/VBN/O ././O
